0.8556
price down icon0.36%   -0.0031
after-market Dopo l'orario di chiusura: .84 -0.0156 -1.82%
loading
Precedente Chiudi:
$0.8587
Aprire:
$0.8655
Volume 24 ore:
77,415
Relative Volume:
0.12
Capitalizzazione di mercato:
$10.36M
Reddito:
-
Utile/perdita netta:
$-7.51M
Rapporto P/E:
-0.6482
EPS:
-1.32
Flusso di cassa netto:
$-8.02M
1 W Prestazione:
+8.63%
1M Prestazione:
-17.73%
6M Prestazione:
+1.86%
1 anno Prestazione:
-26.87%
Intervallo 1D:
Value
$0.8259
$0.8655
Intervallo di 1 settimana:
Value
$0.74
$0.869
Portata 52W:
Value
$0.58
$3.80

Hoth Therapeutics Inc Stock (HOTH) Company Profile

Name
Nome
Hoth Therapeutics Inc
Name
Telefono
(646)756-2997
Name
Indirizzo
1177 AVENUE OF THE AMERICAS, NEW YORK, NY
Name
Dipendente
3
Name
Cinguettio
Name
Prossima data di guadagno
2024-11-11
Name
Ultimi documenti SEC
Name
HOTH's Discussions on Twitter

Confronta HOTH con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
HOTH
Hoth Therapeutics Inc
0.8556 10.36M 0 -7.51M -8.02M -1.32
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
493.84 125.74B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
602.64 61.57B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
614.76 36.40B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
251.56 30.36B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
244.90 24.89B 3.81B -644.79M -669.77M -6.24

Hoth Therapeutics Inc Stock (HOTH) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2019-10-15 Iniziato The Benchmark Company Speculative Buy

Hoth Therapeutics Inc Borsa (HOTH) Ultime notizie

pulisher
Apr 21, 2025

Quarterly Snapshot: Quick and Current Ratios for Hoth Therapeutics Inc (HOTH) - DWinneX

Apr 21, 2025
pulisher
Apr 18, 2025

Hoth Therapeutics’ (HOTH) “Buy” Rating Reiterated at D. Boral Capital - Defense World

Apr 18, 2025
pulisher
Apr 18, 2025

Hoth secures Japan patent for RNA cancer therapy targeting KIT gene - Investing.com Canada

Apr 18, 2025
pulisher
Apr 17, 2025

Hoth secures Japan patent for RNA cancer therapy targeting KIT gene By Investing.com - Investing.com South Africa

Apr 17, 2025
pulisher
Apr 17, 2025

Revolutionary RNA Cancer Treatment Gets Japanese Patent: Hoth's KIT Gene Therapy Targets Multiple Cancers - Stock Titan

Apr 17, 2025
pulisher
Apr 16, 2025

Hoth Therapeutics (HOTH) Reports Promising Phase 2a Results for Pruritus Treatment | HOTH Stock News - GuruFocus

Apr 16, 2025
pulisher
Apr 15, 2025

Hoth Therapeutics reports progress in pruritus treatment trial By Investing.com - Investing.com South Africa

Apr 15, 2025
pulisher
Apr 15, 2025

Hoth Therapeutics Announces Positive Initial Data In Phase 2A Clinical Trial - TradingView

Apr 15, 2025
pulisher
Apr 15, 2025

Hoth Therapeutics reports progress in pruritus treatment trial - Investing.com

Apr 15, 2025
pulisher
Apr 15, 2025

Breakthrough: New Cancer Drug Cuts Treatment Side Effects in HalfPhase 2a Success - Stock Titan

Apr 15, 2025
pulisher
Apr 03, 2025

Hoth Therapeutics reports Alzheimer’s drug candidate success By Investing.com - Investing.com Nigeria

Apr 03, 2025
pulisher
Apr 02, 2025

Hoth Therapeutics (HOTH) Reports Promising Data for Alzheimer's Candidate HT-ALZ - GuruFocus

Apr 02, 2025
pulisher
Apr 02, 2025

Hoth Flat on Hookup with Washington Univ. - Baystreet.ca

Apr 02, 2025
pulisher
Apr 02, 2025

Hoth Therapeutics reports Alzheimer’s drug candidate success - Investing.com India

Apr 02, 2025
pulisher
Apr 02, 2025

Hoth Therapeutics Plans To Advance HT-ALZ Into Clinical Development - MarketScreener

Apr 02, 2025
pulisher
Apr 02, 2025

Hoth Therapeutics Collaborates with Washington University on NIH Grant Application Advancing Alzheimer's Program Using NK-1 Receptor Antagonist HT-ALZ - Longview News-Journal

Apr 02, 2025
pulisher
Apr 02, 2025

Hoth Therapeutics Announces Positive Pre Clinical Data HT-ALZ Shows Promising Breakthrough in Alzheimer's Disease Research Acute treatment with HT-ALZ led to a rapid (~15%) reduction in brain interstitial fluid Aβ levels, within 20 hours - PR Newswire

Apr 02, 2025
pulisher
Apr 01, 2025

Hoth Therapeutics (NASDAQ:HOTH) Receives “Buy” Rating from D. Boral Capital - Defense World

Apr 01, 2025
pulisher
Mar 31, 2025

Hoth Therapeutics receives USPTO filing receipt for HT-001 patent application - TipRanks

Mar 31, 2025
pulisher
Mar 31, 2025

Hoth Therapeutics Receives USPTO Filing Receipt for HT-001 Formulation Patent Application, Expanding Existing Patent Coverage - PR Newswire

Mar 31, 2025
pulisher
Mar 31, 2025

New Patent Filing Strengthens Hoth's Cancer Treatment IP PortfolioKey Details - Stock Titan

Mar 31, 2025
pulisher
Mar 28, 2025

Hoth Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Mar 28, 2025
pulisher
Mar 28, 2025

Hoth Therapeutics Inc. (HOTH) reports earnings - Quartz

Mar 28, 2025
pulisher
Mar 28, 2025

Hoth Therapeutics, Inc. SEC 10-K Report - TradingView

Mar 28, 2025
pulisher
Mar 26, 2025

Hoth Therapeutics enhances patent claims, begins toxicity study By Investing.com - Investing.com South Africa

Mar 26, 2025
pulisher
Mar 26, 2025

Hoth Therapeutics enhances patent claims, begins toxicity study - Investing.com

Mar 26, 2025
pulisher
Mar 26, 2025

Hoth Therapeutics Advances Cancer Fighting HT-KIT Program with New Patent Filing and Preclinical Study Initiation - Marketscreener.com

Mar 26, 2025
pulisher
Mar 26, 2025

Major Progress: Hoth's Cancer-Fighting Drug Secures Patent Protection and Launches Critical Safety Study - Stock Titan

Mar 26, 2025
pulisher
Mar 24, 2025

Hoth Therapeutics Inc expected to post a loss of 37 cents a shareEarnings Preview - TradingView

Mar 24, 2025
pulisher
Mar 20, 2025

Hoth Therapeutics (HOTH) Projected to Post Earnings on Thursday - Defense World

Mar 20, 2025
pulisher
Mar 19, 2025

Balance Sheet Breakdown: Hoth Therapeutics Inc (HOTH)’s Debt-to-Equity and Long-Term Debt/Eq Ratios - The Dwinnex

Mar 19, 2025
pulisher
Mar 19, 2025

Hoth Therapeutics announces ‘positive’ results from study of HT-KIT - Yahoo Finance

Mar 19, 2025
pulisher
Mar 19, 2025

Hoth reports progress in GIST treatment with HT-KIT By Investing.com - Investing.com Australia

Mar 19, 2025
pulisher
Mar 18, 2025

Hoth reports progress in GIST treatment with HT-KIT - Investing.com India

Mar 18, 2025
pulisher
Mar 18, 2025

Hoth Therapeutics Announces Positive Preclinical Results for HT-KIT in Aggressive Cancer Gastrointestinal Stromal Tumors (GIST). HT-KIT Triggered Significant Tumor Cell Death as Early as 24 Hours Post-treatment - PR Newswire

Mar 18, 2025
pulisher
Mar 18, 2025

Revolutionary 24-Hour Cancer Treatment Success: Hoth's HT-KIT Destroys GIST Tumors in Breakthrough Study - Stock Titan

Mar 18, 2025
pulisher
Mar 17, 2025

Short Interest in Hoth Therapeutics, Inc. (NASDAQ:HOTH) Decreases By 24.8% - Defense World

Mar 17, 2025
pulisher
Mar 10, 2025

Hoth Therapeutics to submit HT-001 expanded access application By Investing.com - Investing.com Australia

Mar 10, 2025
pulisher
Mar 10, 2025

Hoth Therapeutics Announces Plans To Submit Expanded Access Application For Ht-001 To Support Cancer Patients In Need - Marketscreener.com

Mar 10, 2025
pulisher
Mar 10, 2025

Hoth Dips on Drug Application - Baystreet.ca

Mar 10, 2025
pulisher
Mar 10, 2025

Hoth Therapeutics to submit Expanded Access application for HT-001 - TipRanks

Mar 10, 2025
pulisher
Mar 10, 2025

Hoth Therapeutics to submit HT-001 expanded access application - Investing.com India

Mar 10, 2025
pulisher
Mar 10, 2025

Hoth Therapeutics Announces Plans to Submit Expanded Access Application for HT-001 to Support Cancer Patients in Need - PR Newswire

Mar 10, 2025
pulisher
Mar 05, 2025

Hoth Therapeutics reports HT-001 cream success in skin toxicity By Investing.com - Investing.com South Africa

Mar 05, 2025
pulisher
Mar 05, 2025

Hoth Therapeutics reports HT-001 cream success in skin toxicity - Investing.com India

Mar 05, 2025
pulisher
Mar 05, 2025

Hoth Therapeutics reports ‘promising’ results for HT-001 therapeutic candidate - TipRanks

Mar 05, 2025

Hoth Therapeutics Inc Azioni (HOTH) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$20.59
price up icon 0.24%
$69.69
price up icon 1.06%
$32.20
price up icon 0.53%
$23.46
price down icon 36.06%
$102.02
price down icon 15.36%
biotechnology ONC
$244.90
price down icon 4.40%
Capitalizzazione:     |  Volume (24 ore):